U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07646080) titled 'Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma Protuberans' on April 14.
Brief Summary: This study aims to evaluate the efficacy and safety of toripalimab and anlotinib hydrochloride combined with standard chemotherapy in patients with refractory dermatofibrosarcoma protuberans (DFSP) resistant to imatinib therapy, and to provide evidence for the exploration of DFSP treatment.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Dermatofibrosarcoma Protuberans (DFSP)
Intervention:
DRUG: Toripalimab
All enrolled patients will receive study interv...